Information Provided By: 
Fly News Breaks for September 30, 2019
IOVA
Sep 30, 2019 | 16:16 EDT
Stifel analyst Benjamin Burnett started Iovance Biotherapeutics with a Buy rating and $27 price target. The analyst says his physician checks corroborate the view that the company's lifileucel and LN-145 data are "very good" and supportive of being the best therapeutic option in their respective advanced settings. He believes the market opportunity for an autologous tumor-infiltrating lymphocyte product in the advanced melanoma/cervical cancer setting can reach $2B-plus sales at peak.
News For IOVA From the Last 2 Days
There are no results for your query IOVA
